Format

Send to

Choose Destination
See comment in PubMed Commons below
P T. 2012 Jul;37(7):405-11.

Hydroxyprogesterone caproate injection (makena) one year later: to compound or not to compound that is the question.

Abstract

Preterm births have increased by 27% over the last decade in the U.S. The main ingredient in Makena, 17P, is less expensive at compounding pharmacies, but this method is not FDA-approved. The authors discuss the quality, safety, and use of Makena and compounded 17P; the potential for liability; cost considerations; and recommended restrictions for the product's use.

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Write to the Help Desk